The need to provide outcome-based medicine can lead to operational inefficiencies in scheduling and performing unnecessary procedures due to uncertain results.
The first automated, accurate and reproducible quantification for 99mTc, 123I, 177Lu, 111In, and 131I2, xSPECT Quant™ extends advanced SPECT quantification from general nuclear medicine and bone studies to indications including neurological disorders, neuroendocrine tumors, neuroblastoma, thyroid, and prostate cancers.
xSPECT Quant is the first and only technology to use a 3% National Institute of Standards and Technology (NIST) traceable precision source3, enabling standardization of uptake values across different cameras, dose calibrators and facilities, for reliable disease detection and evaluation of therapy response.
The absolute quantification capabilities of xSPECT Quant also can facilitate theranostics, an emerging approach employing radioactive isotopes that emit energies to not only image but also treat the patient’s disease.